Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Taieb

Showing results (1-10 of 343) with videos related to

Pageof 35
Sort By:
Bulletin De L'Academie Nationale De Medecine|August 2, 2016
[Quality of life during and after therapy]Julien Taieb
Nature Reviews. Clinical Oncology|December 1, 2025
When ctDNA says 'maybe': improving the dynamics of MRD trialsJulien Taieb
The Lancet. Gastroenterology & Hepatology|March 11, 2019
How best to treat older patients with metastatic colorectal cancer?Julien Taieb
JAMA Oncology|July 14, 2018
Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer-ReplyJulien Taieb
The British Journal of Surgery|September 8, 2025
Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancerJulien Taieb, Mehdi Karoui
Bulletin Du Cancer|May 20, 2018
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]Thierry André, Julien Taieb,
ESMO Open|August 21, 2020
How I treat pancreatic cancerJulien Taieb, Raëf Abdallah
Translational Gastroenterology and Hepatology|March 12, 2019
How to better select patients with advanced gastric cancer for immunotherapyAziz Zaanan, Julien Taieb
Cancers|September 23, 2020
Adjuvant Chemotherapy for Stage III Colon CancerJulien Taieb, Claire Gallois
Bulletin Du Cancer|December 12, 2018
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]Aziz Zaanan, Julien Taieb
Pageof 35

Showing results (1-10 of 343) with videos related to

Sort By:
Pageof 35
Bulletin De L'Academie Nationale De Medecine|August 2, 2016
[Quality of life during and after therapy]Julien Taieb
Nature Reviews. Clinical Oncology|December 1, 2025
When ctDNA says 'maybe': improving the dynamics of MRD trialsJulien Taieb
The Lancet. Gastroenterology & Hepatology|March 11, 2019
How best to treat older patients with metastatic colorectal cancer?Julien Taieb
JAMA Oncology|July 14, 2018
Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer-ReplyJulien Taieb
The British Journal of Surgery|September 8, 2025
Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancerJulien Taieb, Mehdi Karoui
Bulletin Du Cancer|May 20, 2018
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]Thierry André, Julien Taieb,
ESMO Open|August 21, 2020
How I treat pancreatic cancerJulien Taieb, Raëf Abdallah
Translational Gastroenterology and Hepatology|March 12, 2019
How to better select patients with advanced gastric cancer for immunotherapyAziz Zaanan, Julien Taieb
Cancers|September 23, 2020
Adjuvant Chemotherapy for Stage III Colon CancerJulien Taieb, Claire Gallois
Bulletin Du Cancer|December 12, 2018
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]Aziz Zaanan, Julien Taieb
Pageof 35